Figure 3.

(A) Cost-effectiveness plane with y axis representing the incremental capital cost (US Dollars) of our training center for requisite simulation facilities and x axis representing the ICO OSCAR phaco score in operating theater performance. The blue line illustrates the incremental cost-effectiveness ratio (ICER) of Group A (Eyesi + Wet laboratory phacoemulsification with synthetic eyes + Wet laboratory with porcine eyes) relative to Group B (Wet laboratory phacoemulsification with synthetic eye + Wet laboratory with porcine eyes), the yellow line illustrates the ICER of Group A relative to Group C (Wet laboratory with porcine eyes), and the gray line illustrates the ICER of Group B relative to Group C. (B) Cost-effectiveness plane with y axis representing the incremental recurring cost per annum (US Dollars) of trainee participation in simulation module(s) and x axis representing the incremental ICO OSCAR phaco score in operating theater performance. The blue line illustrates the ICER of Group A (Eyesi + Wet laboratory phacoemulsification with synthetic eyes + Wet laboratory with porcine eyes) relative to Group B (Wet laboratory phacoemulsification with synthetic eye + Wet laboratory with porcine eyes), the yellow line illustrates the ICER of Group A relative to Group C (Wet laboratory with porcine eyes), and the gray line illustrates the ICER of Group B relative to Group C. ICER, incremental cost-effectiveness ratio, ICO OSCAR phaco = International Council of Ophthalmology Surgical Competency Assessment Rubric—phacoemulsification.